Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

AHP presents newest PTPase inhibitors with blood glucose-lowering activity

Sep. 27, 2000

Zometa deemed approvable by FDA

Sep. 27, 2000

Vivus seeks FDA approval to begin female sexual dysfunction trial

Sep. 27, 2000

Research program at SB on orexin receptor antagonists yields results

Sep. 26, 2000

Merck discusses preparation and methods of using integrin antagonists for bone disorders, etc.

Sep. 26, 2000

Inhibitors of ileal bile acid transport synthesized at Pharmacia

Sep. 25, 2000

Contraceptive agents under investigation at French research institute

Sep. 25, 2000

Novel calcilytic compounds useful for bone disorders

Sep. 22, 2000

Preparation and use of new compounds inhibiting fat accumulation described by Sumitomo

Sep. 22, 2000

Genzyme General's BLA for Fabry's disease accepted by FDA

Sep. 22, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...